ICON PLC
NASDAQ:ICLR

Watchlist Manager
ICON PLC Logo
ICON PLC
NASDAQ:ICLR
Watchlist
Price: 188.67 USD 3.54% Market Closed
Market Cap: 14.4B USD

ICLR's latest stock split occurred on Aug 13, 2008

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

Before the split, ICLR traded at 82.54 per share. Afterward, the share price was about 43.16.

The adjusted shares began trading on Aug 13, 2008. This was ICLR's 2nd stock split, following the previous one in Oct 24, 2006.

Last Splits:
Aug 13, 2008
2-for-1
Oct 24, 2006
2-for-1
Pre-Split Price
41.27 82.54
Post-Split Price
43.16
Before
After
Last Splits:
Aug 13, 2008
2-for-1
Oct 24, 2006
2-for-1

ICON PLC
Stock Splits History

ICLR Stock Splits Timeline
Aug 13, 2008
Aug 13, 2008
Split 2-for-1
x2
Pre-Split Price
41.27 82.54
Post-Split Price
43.16
Before
After
Oct 24, 2006
Oct 24, 2006
Split 2-for-1
x2
Pre-Split Price
18.705 74.82
Post-Split Price
19.06
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.13 0.13 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.41 8.41 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Dec 30, 2025
Adicet Bio Inc
NASDAQ:ACET
1-for-16
/16
0.4921 0.4921 USD 7.93 7.93 USD
Load More

ICON PLC
Glance View

In the rapidly evolving landscape of global healthcare, ICON PLC stands out as a formidable player, seamlessly bridging the gap between innovative drug development and practical clinical application. Founded in Dublin, Ireland, ICON has grown into a multinational enterprise, deeply embedded in the research and development phases of various medical and biopharmaceutical companies. The company's core strength lies in its ability to offer comprehensive clinical trial services, encompassing every stage of drug development, from initial study design through to final data management and regulatory submissions. ICON's systematic approach not only shortens the timeline for bringing novel therapeutics to market but also ensures that these breakthroughs are both effective and safe, thereby garnering trust from clients ranging from burgeoning biotech startups to pharmaceutical giants. As a contract research organization (CRO), ICON operates within a business model designed to capitalize on the booming demand for outsourced R&D support. This model involves entering into strategic partnerships with clients to conduct all necessary research activities in exchange for fees, which can be structured through agreements for specific projects or longer-term collaborations. The company leverages its robust network, sophisticated technological platforms, and expert workforce to offer tailored solutions that optimize efficiency and accuracy. By doing so, ICON not only enhances its clients’ product pipelines but also secures a steady stream of revenue, further consolidated through repeat business and the expansion of its service repertoire to include emerging areas like digital health and real-world evidence. This disciplined and innovative approach propels ICON's growth, ensuring its financial health and reaffirming its integral role in driving medical advancement worldwide.

ICLR Intrinsic Value
274.89 USD
Undervaluation 31%
Intrinsic Value
Price
Back to Top